

# CaNIOS Newsletter

VOL. 9 NO. 7

July 2009

www.CaNIOS.ca



## Important Dates

**June 26, 2009** - ACR  
Abstract deadline

**February 3-6, 2010** CRA  
Conference, Chateau Fron-  
tenac, Quebec City

**June 24, 2010** – CaNIOS  
Business Meeting

**June 24-27, 2010** – 9th  
International Congress on  
SLE, Vancouver, BC.

## INSIDE:

Abstracts submitted	p2
Papers submitted	p2
Manuscripts in prepa- ration	p2
Recruitments	p3



## ACR Abstracts Submitted

The ACR Abstract submission deadline has passed, and several interesting findings were submitted by different CaNIOS ongoing

studies. CaNIOS submitted a record total of 13 Abstracts for GenES, 1000 Faces, ThromboFIL, HIPP, and LuNNET. A complete

list of submitted CaNIOS abstracts can be found on page 2.

## 1000 Faces Publications

Two manuscripts from the 1000 Faces of Lupus Study have recently been accepted for publication. The manuscript by Baker et al. entitled "Work Disability in Systemic Lupus Erythematosus is Prevalent and Predicted by Socio-demographic and Disease Related Factors" has been accepted in the journal Lupus; and Colangelo, Pope, Peschken's "The minimally important difference (MID) for patient reported outcomes in systemic lupus

erythematosus (SLE) including the HAQ-DI, pain, fatigue and SF-36" has been accepted in Journal of Rheumatology. In total, 4 manuscripts have come out of 1000 Faces study including "The 1000 Canadian Faces of Lupus: Determinants of Disease Outcome in a Large Multi-Ethnic Cohort by Peschken et al. published in Journal of Rheumatology," and Barriers to Healthcare in a Multiethnic Cohort of Systemic Lupus Erythemat-

osus (SLE) patients: Patient and Physician Perceptions by Law et al. published in Clinical Medicine: Arthritis and Musculoskeletal Disorders. Two other manuscripts are currently under peer review, and several other manuscripts will be written in the coming months based on abstracts submitted to the ACR, including analysis on medication, and Geographic Information Systems analysis on the 1000 Faces cohort.

## LuNNET Prepares for Grant Renewal

LuNNET is now in its last year of funding. Since there are no forthcoming CIHR grant competition that would allow the Lupus Nephritis New Emerging Team to move on as a Team Grant, the renewal will be

submitted to CIHR as an operating grant in the fall. Several CaNIOS Centres have indicated their willingness to participate in this study mostly through one-time enrolment by providing paired kidney biops-

urine/blood samples. The LuNNET core team members have been meeting regularly to define the focus and objectives of the grant. Expect requests for letters of collaboration in the summer months.

## Lady Luck Awaits Us Next

CIHR has released the reviews of the Spring 2009 Open Operating Grant competition. If you recall, CaNIOS submitted 3 renewal grants last March, GenES Phase 2, ThromboFIL

Phase 2, and 2000 Faces Study. Although formal notifications are yet to be sent by CIHR, none of our submissions were ranked above 10 which means these studies will likely be funded

only in future competition. When 3 doors close at once, Lady Luck surely will open more doors with a pleasant smile next.

### CaNIOS Authorship Definition

To be a named author in any CaNIOS publication, one must meet conditions 1, 2, and 3 below:

- (1) Substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;
- (2) Drafting the article or revising it critically for important intellectual content; and
- (3) Final approval of the version to be published.

### ACR Abstracts Submitted

Cooper GS, Wither JE, Bernatsky SR, Claudio JO, Clarke AE, Rioux JD, Paterson A, Fortin PR. **New Directions For Environmental Research: Results from the Genetic and Environmental Factors in Systemic Lupus Erythematosus**

Aghdassi E, Zhang W, St-Pierre Y, Clarke AE, Morrison S, Su J, Landolt-Marticorena C, Reich H, Scholey J, Herzenberg A, CaNIOS Investigators, Wither J, Fortin PR. **Health Care Resource Utilization & Loss of Productivity in a Canadian Population of Patients With & Without Lupus Nephritis.**

Bernatsky S, Peschken C, Fortin, PR, Gladman D, Pope J, Clarke A, CaNIOS Investigators. **Medication Use in Systemic Lupus Erythematosus (SLE).**

Jeyalingam T, Su J, Brown P, Peschken CA, Pope J E, CaNIOS Investigators, Fortin PR. **Distance to Lupus Centre AND Health Care Barriers in Systemic Lupus Erythematosus.**

Al-Dhanhani A, Su J, Pineau C, Pope J, Morrison S, Agdhassi E, DaCosta D, Fortin PR. **Non-Adherence to Medication Among Lupus Patients**

Yip J, Aghdassi E, Su J, Bargman J, Reich H, Lou W and Fortin PR. **Serum Albumin as a Marker for Disease Activity in Systemic Lupus Erythematosus (SLE) in Patients with and without Renal Involvement.**

Zhang W, Aghdassi E, Reich H, Scholey J, Su J, Fortin PR. **Baseline EGFR Is Predictive of Cardiovascular Diseases in Patients with Systemic Lupus Erythematosus (SLE).**

Neville, Rauch J, Kassis J, Solymoss S, Lawrence J, Belisle P, Fortin PR. **Anti-phospholipid antibodies predict future arterial but not venous events at 10 years of follow up.**

Landolt-Marticorena C, Morrison S, Reich H, Agdhassi E, Herzenberg A, Scholey J, Gladman D, Urowitz M, Fortin PR, Wither JE. **Clinical Utility Of Changes In Cyto/Chemokines As Markers Of Disease Activity In Systemic Lupus Erythematosus.**

Tekano J, Tucker LB, Huber Z, Ramsey SE, Silverman E, Chedeville G, Peschken CA, CaNIOS Investigators. **Immunosuppressive Drugs in Juvenile-Onset Lupus: The 1000 Canadian Faces of Lupus Study**

Peschken CA, Pope J, Silverman E, Fortin PR, Pineau C, Zummer M, Urowitz M, Gladman D, Hudson M, Tucker L, Chedeville G, Huber A, Bernatsky S, Clarke A, Smith CD, Arbillaga H, Ramsey SE, and CaNIOS Investigators. **Lupus in Asian Canadians: The 1000 Canadian Faces of Lupus Study.**

Morrison S, Aghdassi E, Pineau C, Pope J, DaCosta D, Fortin PR. **Associations Between Psychological Symptoms and Disease Activity in Female Patients with Systemic Lupus Erythematosus. Abstract#13080.**

Landolt-Marticorena C, Reich H, Morrison S, Aghdassi E, Pineau C, Scholey J, Gladman D, Urowitz M, Herzenberg A, Fortin PR, Wither J. CaNIOS Investigators. **Urinary Cyto/Chemokines Correlates with Renal Histopathology in Systemic Lupus Erythematosus**

## CaNIOS STUDY ENROLLMENT

<b>1000 Faces of Lupus – Enrolled = 1932</b>	
Centre 01 MUHC-MGH	309
Centre 04 Maisonneuve Rosemont	95
Centre 07 Ottawa Hospital	85
Centre 08 London	248
Centre 10 Winnipeg HSC	267
Centre 15 Vancouver ARC	22
Centre 17 TWH CPSRD	575
Centre 19 TWH Non-CPSRD	35
Centre 20 Sick Kids, Toronto	153
Centre 21 BC Children's Hosp.	62
Centre 22 Halifax's IWK HC	11
Centre 26 Lethbridge	27
Centre 27 Montreal Child. Hosp.	20
Centre 33 Jewish General Hosp.	23

<b>HIPP – Randomized = 289</b>	
<b>Recruitment Closed</b>	
<b>GenES Phase I (Recruitment Closed)</b>	
<b>ThromboFIL (Recruitment Closed)</b>	

<b>LuNNET Cohort 2 (Including 2B and 2C) = 76</b>		
Centre 17 TWH CPS	68	Cohort 2 n = 28 Cohort 2B n = 37 Cohort 2C n = 11 Total n = 76
Centre 19 TWH non-CPS	7	
Centre 28 Mt. Sinai	1	
<b>Total</b>	<b>76</b>	
<b>LuNNET Cohort 3 (Prospective Cohort) = 126</b>		
Centre 01 MGH	21	Active SLE with Lupus Nephritis: <b>n = 80</b> Active SLE with out Lupus Nephritis: <b>n = 57</b> In-active SLE with History of Lupus Nephritis: <b>n = 38</b> In-active SLE without History of Lupus Nephritis: <b>n = 27</b>  <b>Total: 202</b>
Centre 08 London	7	
Centre 10 Winnipeg	5	
Centre 17 TWH CPS	90	
Centre 19 TWH non-CPS	4	
<b>Total</b>	<b>126</b>	

### Privacy

If you wish to be unsubscribed from the CaNIOS monthly newsletter e-mail list please contact Jaime O. Claudio, CaNIOS' National S&D Coordinator at:

Tel (416) 603-5800 ext. 3158; Fax: (416) 603-6288;

or e-mail: [jclaudio@uhnresearch.ca](mailto:jclaudio@uhnresearch.ca).

### Contact

CaNIOS Coordinating Centre  
Toronto Western Hospital  
399 Bathurst Street, MP 10-303  
Toronto, ON M5T 2S8, Canada

Phone: 416-603-5800 extension 3158

Fax: 416-603-6288

e-mail: [jclaudio@uhnresearch.ca](mailto:jclaudio@uhnresearch.ca)

Web: [www.CaNIOS.ca](http://www.CaNIOS.ca)

## About CaNIOS

CaNIOS is a unique collaboration that brings together widespread scientific and clinical expertise in a coordinated and collaborative spirit which allows Canadian researchers to address several questions important to patients with lupus and their families. Founded in 1995 when the current chair, Dr. Paul R. Fortin was at the Montreal General Hospital, CaNIOS Coordinating Centre moved to Toronto Western Hospital in 2000. CaNIOS maintains a database of lupus patients through its National Lupus Registry which combines data from different centres through a standardized data collection system. CaNIOS has been supported solely by funding from individual operating grants from governmental agencies and non-for-profit organizations and foundations.